Fox Run Management L.L.C. Has $112,000 Stake in Embecta Corp. $EMBC

Fox Run Management L.L.C. cut its position in shares of Embecta Corp. (NASDAQ:EMBC) by 53.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,571 shares of the company’s stock after selling 13,080 shares during the quarter. Fox Run Management L.L.C.’s holdings in Embecta were worth $112,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of EMBC. CWM LLC raised its position in shares of Embecta by 16.0% in the 2nd quarter. CWM LLC now owns 8,080 shares of the company’s stock worth $78,000 after acquiring an additional 1,115 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after purchasing an additional 1,159 shares in the last quarter. SummerHaven Investment Management LLC lifted its stake in Embecta by 1.9% in the second quarter. SummerHaven Investment Management LLC now owns 66,313 shares of the company’s stock valued at $643,000 after buying an additional 1,268 shares during the period. Jennison Associates LLC boosted its holdings in shares of Embecta by 3.1% during the 2nd quarter. Jennison Associates LLC now owns 55,193 shares of the company’s stock worth $535,000 after buying an additional 1,668 shares in the last quarter. Finally, Inspire Advisors LLC boosted its holdings in shares of Embecta by 9.8% during the 1st quarter. Inspire Advisors LLC now owns 35,475 shares of the company’s stock worth $452,000 after buying an additional 3,168 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Trading Up 1.0%

Shares of NASDAQ:EMBC opened at $14.55 on Friday. The stock has a market cap of $851.03 million, a PE ratio of 10.17, a price-to-earnings-growth ratio of 0.80 and a beta of 1.10. The stock’s fifty day simple moving average is $14.17 and its two-hundred day simple moving average is $12.40. Embecta Corp. has a 1-year low of $9.20 and a 1-year high of $21.48.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. BTIG Research reiterated a “buy” rating and set a $25.00 target price on shares of Embecta in a research report on Friday, September 5th. Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.00.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.